CD63 and prostate carcinoma: Additionally, we found SSX2 is expressed in a CD45−/EpCAM+/CD63+ cell subset in the blood of patients with prostate cancer (Figure 1E), a cell subset specifically representing prostate-specific circulating tumor cells [23].